Researchers led by Alessandro Perencin from the Department of Medicine (DIMED), Geriatrics Division, University of Padua, Italy, conducted a systematic review to examine whether this class of diabetes medications could provide direct kidney benefits. GLP-1 receptor agonists (GLP-1RAs) are already widely prescribed for blood sugar management and cardiovascular protection, but their potential to safeguard kidney health has not been comprehensively evaluated until now.
To assess this possibility, the team performed an extensive search of medical literature across databases such as PubMed, Embase, Web of Science, and the Cochrane Library. They looked for studies that reported kidney-related outcomes—specifically estimated glomerular filtration rate (eGFR), a key measure of kidney function, and albumin-to-creatinine ratio (ACR), an indicator of protein leakage in the urine—in adults with type 2 diabetes who were treated with GLP-1RAs. Each study was carefully reviewed for quality and risk of bias to ensure reliable conclusions.
Thirteen studies, including both randomized clinical trials and observational analyses, met the inclusion criteria. These investigations suggest that GLP-1RAs may slow the progression of kidney damage, reduce proteinuria, and improve other important markers of renal health in patients with diabetes. Several studies showed significant slowing of eGFR decline and reductions in ACR, pointing to a possible protective effect against diabetic kidney disease.
However, the evidence was not entirely consistent. While some studies demonstrated clear and measurable benefits, others reported only modest improvements or no significant impact on kidney function. Differences in study design, patient populations, and treatment duration may partly explain these mixed results.
Despite these variations, the authors underscore that the overall trend is encouraging. With diabetic kidney disease remaining a major cause of chronic kidney failure worldwide, therapies that can both control blood glucose and support kidney health are urgently needed. GLP-1RAs—already known to lower cardiovascular risk—could offer an added advantage by helping to preserve renal function over time.
The review calls for larger, well-structured clinical trials to confirm these preliminary findings and to clarify how GLP-1RAs exert potential nephroprotective effects. Establishing clear evidence could help physicians decide when and how to incorporate these drugs into treatment plans for people with type 2 diabetes who are at risk of kidney complications.
"The systematic review highlights the emerging role of GLP-1 receptor agonists as more than just blood sugar–lowering agents. While further research is necessary, these medications may one day become a cornerstone not only in managing type 2 diabetes and cardiovascular disease but also in protecting long-term kidney health," the authors concluded.
Reference:
Perencin A, Ceolin C, Papa MV, Di Marzio B, Zanforlini BM, Devita M, et al. Glucagon-like peptide-1 receptor agonists and its possible nephroprotective role: a systematic review. Minerva Med 2025 Sep 11. DOI: 10.23736/S0026-4806.25.09709-5
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.